In humans, a copy of the DUX4 retrogene is located in each unit of the D4Z4 macrosatellite repeat that normally comprises 8-100 units. The D4Z4 repeat has heterochromatic features and does not express DUX4 in somatic cells. Individuals with facioscapulohumeral muscular dystrophy (FSHD) have a partial failure of somatic DUX4 repression resulting in the presence of DUX4 protein in sporadic muscle nuclei. Somatic DUX4 derepression is caused by contraction of the D4Z4 repeat to 1-10 units (FSHD1) or by heterozygous mutations in genes responsible for maintaining the D4Z4 chromatin structure in a repressive state (FSHD2). One of the FSHD2 genes is the structural maintenance of chromosomes hinge domain 1 (SMCHD1) gene. SMCHD1 mutations have also been identified in FSHD1; patients carrying a contracted D4Z4 repeat and a SMCHD1 mutation are more severely affected than relatives with only a contracted repeat or a SMCHD1 mutation. To evaluate the modifier role of SMCHD1, we crossbred mice carrying a contracted D4Z4 repeat (D4Z4-2.5 mice) with mice that are haploinsufficient for Smchd1 (Smchd1 MommeD1 mice). D4Z4-2.5/Smchd1 MommeD1 mice presented with a significantly reduced body weight and developed skin lesions. The same skin lesions, albeit in a milder form, were also observed in D4Z4-2.5 mice, suggesting that reduced Smchd1 levels aggravate disease in the D4Z4-2.5 mouse model. Our study emphasizes the evolutionary conservation of the SMCHD1-dependent epigenetic regulation of the D4Z4 repeat array and further suggests that the D4Z4-2.5/ Smchd1 MommeD1 mouse model may be used to unravel the function of DUX4 in non-muscle tissues like the skin. †
Introduction
DUX4 is a double homeobox transcription factor expressed in the luminal cells of the testis (1) and in cleavage stage embryos (2) (3) (4) . A copy of the DUX4 retrogene is located in each unit of the D4Z4 macrosatellite repeat at the subtelomere of chromosome 4q. This D4Z4 repeat is polymorphic in size and typically consists of 8-100 D4Z4 repeat units (5) (6) (7) . In most somatic cells, the D4Z4 repeat has heterochromatic features and, likely due to repeat-mediated epigenetic repression, does not express or rarely expresses DUX4 (1, (8) (9) (10) . Individuals with FSHD, a common inherited myopathy that initially affects muscles of the face, shoulder girdle, and upper arms, have a partial failure of the epigenetic repression of the D4Z4 repeat, resulting in the presence of DUX4 protein in a limited number of muscle nuclei (1) . This failure in epigenetic repression can be caused by contraction of the D4Z4 repeat to 1-10 units (FSHD1) (5, 6) , by heterozygous mutations in the SMCHD1 gene (FSHD2) (11), or in rare cases by heterozygous mutations in the DNA methyltransferase 3B (DNMT3B) gene (FSHD2) (12) . SMCHD1 and DNMT3B both encode chromatin modifiers that seem to be necessary to establish and/or maintain a repressive chromatin structure of the D4Z4 repeat in somatic cells. SMCHD1 and DNMT3B mutations have also been identified in FSHD1 families; patients that carry both a contracted D4Z4 repeat and a FSHD2 mutation present with a more severe clinical phenotype than relatives carrying only the D4Z4 repeat contraction or the SMCHD1/DNMT3B mutation (12) (13) (14) . In agreement, enhanced DUX4 transcript levels were measured in myotube cultures from FSHD1 patients upon SMCHD1 knockdown (13) .
To study the in vivo epigenetic regulation of the D4Z4 repeat locus, we previously generated hemizygous transgenic mice carrying either a control-sized D4Z4 repeat (D4Z4-12.5 mice) or a FSHD-sized D4Z4 repeat (D4Z4-2.5 mice) (15) . In these mice, we demonstrated that the mechanism of epigenetic repression of DUX4 in somatic cells seems to be conserved between mice and man. Control D4Z4-12.5 mice present with DUX4 expression in the germline, but DUX4 is epigenetically repressed in somatic cells. In contrast, D4Z4-2.5 mice fail to efficiently repress DUX4 in somatic cells. As a consequence, sporadic muscle nuclei express relatively abundant amounts of DUX4 protein (15) . Though the FSHD molecular hallmarks are conserved in D4Z4-2.5 mice, we questioned whether modelling FSHD in rodents will elicit the same pathological consequences as in human. This is supported by the notion that, apart from an uncharacterized eye phenotype, D4Z4-2.5 mice appear healthy without obvious signs of a muscular dystrophy phenotype (15) . However, DUX4 overexpression by intramuscular injection with AAV6-DUX4 in mouse skeletal muscle does lead to muscle damage (16) . In addition, a novel FSHD mouse model with musclespecific doxycycline-regulated DUX4 expression presents with a slow progressive degenerative myopathy involving inflammation and fibrosis (17) . The relatively low levels of DUX4 RNA and protein in skeletal muscle in the D4Z4-2.5 mouse model may explain the lack of muscle pathology in these mice. Furthermore, DUX4 protein expression in D4Z4-2.5 mice is restricted to Myog-negative myoblasts, which do not fuse into myotubes (15) . In contrast, in FSHD patients DUX4 protein expression is observed in myosin-positive myotubes (18, 19) . Thus, the transgene spatial and temporal expression pattern may explain the failure of modelling the FSHD muscle phenotype in our D4Z4-2.5 mice.
In the current study, we modelled the digenic requirements of FSHD by crossbreeding D4Z4-2.5 mice with mice that are haploinsufficient for Smchd1 (Smchd1 MommeD1 mice), and we evaluated the modifier role of Smchd1 on disease severity. The Smchd1 MommeD1 mutation, a nonsense Smchd1 mutation in exon 23 (p.Q963X), was identified in an N-ethyl-N-nitrosourea mutagenesis screen for modifiers of epigenetic reprogramming (20) . Smchd1 encodes a well-conserved protein with a C-terminal SMC hinge domain and an N-terminal ATPase domain. In mice, Smchd1 has roles in the establishment and/or maintenance of DNA methylation, in X chromosome inactivation, and in the regulation of some clustered and imprinted genes (21) (22) (23) .
However, its exact function is still unknown. Smchd1
MommeD1 homozygous females die between E9.5 and E11.5, and lack DNA methylation at many X-linked genes, including Hprt1. In contrast, some homozygous males and all heterozygous males and females survive, the latter presenting with normal Hprt1 DNA methylation levels by adulthood (20, 21) .
In this study, we show that Smchd1 haploinsufficiency results in decreased Smchd1 transcript levels with consequences for the chromatin structure of the D4Z4 transgene in the D4Z4-2.5 mouse model. In addition, reduced Smchd1 expression seems to affect specific tissues, most notably the skin and the thymus. D4Z4-2.5/Smchd1
MommeD1 mice present with significantly increased DUX4 transcript levels in muzzle skin and thymus leading to a skin phenotype starting from postnatal day 10 and a severely reduced body weight from postnatal day 12.
Similar, but much milder, skin lesions are also observed in D4Z4-2.5 mice. This mouse model is not the first DUX4 expressing mouse model with a skin and a runting phenotype. The iDUX4 (2.7) mouse carries a doxycycline-inducible DUX4 transgene and presents with a skin phenotype consisting of increased epidermal thickness and nuclear dermal density and the carrier males that survived to birth were severely runted (24) . Importantly, Smchd1 haploinsufficiency does not seem to impact skeletal muscle. DUX4 transcript levels are not or only slightly increased in skeletal muscles of D4Z4-2.5/ Smchd1 MommeD1 mice compared with D4Z4-2.5 mice. Also, the skeletal muscles of the D4Z4-2.5/Smchd1 MommeD1 mice do not show overt muscle pathology. In conclusion, the D4Z4-2.5 mice and the D4Z4-2.5/Smchd1 MommeD1 mice can be used to study the epigenetic regulation of the D4Z4 repeat array. Furthermore, the D4Z4-2.5/Smchd1 MommeD1 mouse model may be suitable to study the function of DUX4 in the skin and the thymus.
Results
Smchd1 haploinsufficiency affects Smchd1 transcript levels, D4Z4 chromatin structure, and potentially DUX4 expression
We showed previously that SMCHD1 binds the D4Z4 repeat in human fibroblast cultures (11) . To determine whether mouse Smchd1 binds the human D4Z4 transgene in the D4Z4-2.5 mouse model, we performed Smchd1 chromatin immunoprecipitation (ChIP) analysis in fibroblasts isolated from three neonatal D4Z4-2.5 mice. This was indeed the case (Fig. 1A) , and we concluded that D4Z4-2.5 mice are a suitable model to evaluate the modifier role of Smchd1 on D4Z4 chromatin structure, DUX4 expression, and disease severity. Next, we determined the effect of the Smchd1 MommeD1 mutation on Smchd1 expression in D4Z4-2.5 mice by crossbreeding a heterozygous Smchd1 MommeD1 male mouse with a hemizygous D4Z4-2.5 female mouse. We then observed that Smchd1 transcript levels were significantly reduced in all tissues tested of hemizygous D4Z4-2.5 mice carrying MommeD1 mice) compared with hemizygous D4Z4-2.5 mice without the Smchd1 MommeD1 mutation (Fig. 1B) . Sanger sequencing showed that only Smchd1 transcripts from the wildtype allele were present (data not shown). Thus, the mutant Smchd1 transcript seems to be rapidly degraded in concordance with a previous report (21) . To determine the effect of the Smchd1 MommeD1 mutation on the chromatin structure of the D4Z4 repeat, we measured DNA methylation at the region just distal to the D4Z4 repeat (25) . We found significantly reduced DNA methylation levels at two CpG dinucleotides in DNA isolated from the tails of D4Z4-2.5/Smchd1 MommeD1 mice compared with D4Z4-2.5 mice (Fig. 1C) . We also detected a significantly lower chromatin compaction score (ChCS; H3K9me3 level, a repressive chromatin mark, corrected for H3K4me2 level, an active chromatin mark) (26) in D4Z4-2.5/Smchd1 MommeD1 mice when we performed histone ChIP analysis using D4Z4-specific primers (9) in fibroblasts isolated from D4Z4-2.5 and D4Z4-2.5/Smchd1
MommeD1 neonates ( Fig. 1D ; P ¼ 0.0108). Previously, we have shown that the ChCS is significantly reduced in both fibroblasts and myoblasts of FSHD patients compared with control individuals (26) , which is why we refrained from testing the ChCS in myoblasts of the mice. Our results suggested that the Smchd1 MommeD1 mutation could potentially affect DUX4 transcript levels by modulating the Figure 2 . Genotype distribution, gender distribution, and body weight are distorted in mice born from D4Z4-2. crossbreedings have been genotyped. We found that at postnatal day 12 the genotype distribution of the pups that were born from these crossbreedings was significantly distorted ( Fig. 2A ; P ¼ 0.0054). This is probably because fewer D4Z4-2.5/ Smchd1 MommeD1 mice were born, but more pups need to be genotyped to statistically confirm this hypothesis. In addition, less female mice were present at postnatal day 12 ( Fig. 2B ; P ¼ 0.0003). We furthermore observed that during the first days after birth the D4Z4-2.5/Smchd1 MommeD1 mice gained weight and were able to feed, as evidenced by stomachs filled with milk. However, D4Z4-2.5/Smchd1 MommeD1 mice, both males and females, presented with a runting phenotype; the mice were smaller and exhibited an approximate 25% reduction in body weight compared with their littermates at postnatal day 15, although there was considerable variation in body weight reduction ( Fig. 2C ; P < 0.0001). We followed a cohort of 21 D4Z4-2.5/Smchd1 MommeD1 mice from postnatal day 12 and found that 7 D4Z4-2.5/Smchd1 MommeD1 mice (all males) quickly lost body weight. These mice were therefore euthanized at postnatal day 15. In contrast, the other 14 D4Z4-2.5/ Smchd1 MommeD1 mice (10 males and 4 females) retained or gained body weight from 12 days until 22 days of age ( Fig. 2D ). Due to the large difference in body weight compared with littermates with other genotypes, all remaining D4Z4-2.5/Smchd1 MommeD1 mice were euthanized at postnatal day 22. In conclusion, a nonMendelian inheritance pattern is observed for the pups born from D4Z4-2.5/Smchd1
MommeD1 crossbreedings, and D4Z4-2.5/ Smchd1
MommeD1 mice are runted.
Skeletal muscles of the D4Z4-2.5 mouse are relatively insensitive to reduced Smchd1 levels
We previously reported low and variable DUX4 expression in skeletal muscles of D4Z4-2.5 mice (15) . To determine whether Smchd1 has a modifier role by regulating DUX4 expression in vivo, we quantified DUX4 transcript levels in four different skeletal muscles of D4Z4-2.5 and D4Z4-2.5/Smchd1
MommeD1 mice [gastrocnemius muscle, masseter muscle, quadriceps muscle, and tibialis anterior (TA) muscle]. DUX4 expression was significantly increased in only one of the tested muscles of the D4Z4-2.5/Smchd1 MommeD1 mice compared with the D4Z4-2.5 mice, namely only in the quadriceps muscle ( Fig. 3A ; P ¼ 0.0006). In addition to the very low DUX4 transcript levels (Cq values varied between 30 and 35), a possible explanation for this observation may be the prominent interindividual variability in DUX4 expression that we observed. In addition, the skeletal muscles of D4Z4-2.5/Smchd1 MommeD1 mice did not show overt skeletal muscle pathology, as tested by haematoxylin and eosin (H&E) staining of the quadriceps muscle and the TA muscle (Fig. 3B) . Therefore, we hypothesized that skeletal muscles of the D4Z4-2.5 mouse are relatively insensitive to reduced Smchd1 levels. To further address this hypothesis, we studied the D4Z4-2.5/ Smchd1 CKO mouse model. This mouse model was generated by crossbreeding the D4Z4-2.5 mouse model with mice that carry exon 4 of Smchd1 floxed (Smchd1 fl/fl mice) and express Cre recombinase from the muscle-specific promoter Myf5 (27 Del/Del mice were observed at weaning (99 pups were tested). This is consistent with the expected embryonic lethality of a null allele on the C57BL/6 background (21). Both male (n ¼ 8) and female (n ¼ 5) Smchd1 Del/Del embryos were observed at E12.5 and loss of the Smchd1 protein in these embryos was confirmed by Smchd1 western blot (Fig. 3C ). However, all females were very small, consistent with mid-gestation lethality as observed for other Smchd1 null alleles (21) . As Smchd1 was first identified using a multicopy GFP transgene array, directed to express in red blood cells (20, 21) , we also tested the effect of the floxed and deleted alleles on the expression of the GFP3C transgene. We found no changes in expression with the floxed allele, but an increased expression in Smchd1 Del/þ mice (Fig. 3D) , confirming that the floxed allele behaves as a wildtype allele and the deleted allele as a null allele. In the D4Z4-2.5/Smchd1 CKO mice we tested, the Smchd1 gene was disrupted on both alleles in Myf5-positive cells (Fig. 3E) . DUX4 transcript levels were not significantly increased in the complete gastrocnemius muscle (Fig. 3F ), but we did measure increased DUX4 expression in muscle cultures generated from the gastrocnemius muscle (Fig. 3G) , which is in line with our results obtained in D4Z4-2.5/Smchd1 MommeD1 mice. Furthermore, D4Z4-2.5/Smchd1 CKO mice presented with no additional phenotypes compared with D4Z4-2.5 mice; also no muscular dystrophy phenotype was detected by H&E staining (Fig. 3H) . Together, these data indeed suggest that skeletal muscles of the D4Z4-2.5 mouse are largely unaffected by reduced Smchd1 levels.
D4Z4-2.5/Smchd1
MommeD1 mice develop skin hyperkeratosis and alopecia at young age, while D4Z4-2.5 mice present with a mild skin phenotype at 9 weeks of age
Besides the runting phenotype, D4Z4-2.5/Smchd1 MommeD1 mice developed alopecic and hyperkeratotic areas around the nose (muzzle skin), on the dorsal aspect of all paws, and in approximately 10% of cases on the upper back of the trunk region, starting at 10 days of age (Fig. 4A ). The hyperkeratotic skin had a scaly appearance. The skin lesions appeared in all mice and no gender differences were observed. In addition, between postnatal days 11 and 14, when littermates started to open their eyes, the D4Z4-2.5/Smchd1 MommeD1 mice had difficulties opening their eyes (Fig. 4A ). Similar to the skin phenotype, the penetrance of this phenotype was 100% and not gender-dependent. To gain more insight into these phenotypes, we performed histopathological examination of the mice at postnatal day 15. Serial sections of complete heads of the D4Z4-2.5/Smchd1 MommeD1 mice (n ¼ 3) revealed, particularly in the areas around the muzzle and the eyelids, thickening of the stratum corneum with increased layers of keratin (orthokeratotic and parakeratotic hyperkeratosis), thickening of the epidermis reaching 8-10 layers (epidermal hyperplasia) with irregular rete ridges formations (downward projections of the epidermis) (Fig. 4B) , and minimal lymphocytic inflammation in the dermis (Fig. 4C) . In contrast, histopathological investigation of the complete heads of juvenile wild-type mice (n ¼ 3), Smchd1 MommeD1 mice (n ¼ 3), and D4Z4-2.5 mice (n ¼ 3) was normal with no skin lesions apparent at 15 days of age ( Fig. 4B and C). Gross and histological examination of all organs revealed no abnormalities for all four genotypes tested at postnatal day 15 (data not shown).
As shown previously, approximately 50% of D4Z4-2.5 mice develop eye abnormalities, possibly due to incomplete closure of the eyelids. The typical onset of the eye phenotype in D4Z4-2.5 mice is around 8-12 weeks of age (15) . In our current study, histopathological examination did not reveal skin abnormalities that could explain these eye abnormalities in D4Z4-2.5 mice at postnatal day 15. To test whether D4Z4-2.5 mice develop a skin phenotype in adulthood, we performed an additional histopathological examination of complete heads at 9 weeks of age and compared control D4Z4-12.5 mice (n ¼ 3) with D4Z4-2.5 mice (n ¼ 3). A mild skin phenotype consisting of hyperkeratosis was indeed observed around the muzzle and the eyelids of D4Z4-2.5 mice, while no skin pathology was observed in the D4Z4-12.5 mice (Fig. 4D) . Thus, D4Z4-2.5 mice, like D4Z4-2.5/ Smchd1 MommeD1 mice, present with eye and skin phenotypes.
However, these phenotypes develop earlier and are more severe in D4Z4-2.5/Smchd1 MommeD1 mice, as is expected from the hypothesized modifier role of Smchd1 at the D4Z4 repeat array.
Skin and thymus of the D4Z4-2.5 mouse are sensitive to Smchd1 haploinsufficiency
The phenotype of D4Z4-2.5/Smchd1 MommeD1 mice seems restricted to the body weight and the skin, with consequences for the eyes. We therefore hypothesized that skin tissue is more sensitive to Smchd1 haploinsufficiency and presents with higher DUX4 transcript levels than skeletal muscles and other nonskeletal muscle tissues. To test our hypothesis, we measured DUX4 transcript levels in muzzle skin and in additional nonskeletal muscle tissues, namely brain (cerebellum), heart, testis, and thymus. Indeed, DUX4 expression was significantly increased in the muzzle skin of D4Z4-2.5/Smchd1 MommeD1 mice compared with D4Z4-2.5 mice ( Fig. 5A ; P ¼ 0.0004), whereas DUX4 transcript levels in the cerebellum, heart, and testis were unchanged (Fig. 5B) . Unexpectedly, DUX4 expression was also significantly increased in the thymus of D4Z4-2.5/Smchd1 MommeD1 mice ( Fig. 5A ; P ¼ 0.0011). We also tested the expression of the DUX4 target gene Wfdc3 (15) in muzzle skin and thymus, and observed a significant increase in Wfdc3 transcript levels in both tissues of D4Z4-2.5/Smchd1 MommeD1 mice ( Fig. 5C ; P < 0.01). Interestingly, DUX4 expression in the thymus of D4Z4-2.5/Smchd1
MommeD1 mice was highly variable. Of the eight mice tested, only three D4Z4-2.5/Smchd1 MommeD1 mice showed increased DUX4 expression in the thymus compared with D4Z4-2.5 mice. We found an inverse relationship between the thymus weight and DUX4 expression in the thymus; the D4Z4-2.5/Smchd1 MommeD1 mice with the lowest thymus weight presented with the highest DUX4 transcript levels ( Fig. 5A and D) . We also observed that the body weight of the D4Z4-2.5/Smchd1 MommeD1 mice with the highest DUX4 expression in the thymus was significantly reduced compared with D4Z4-2.5/Smchd1 MommeD1 mice with lower DUX4 transcript levels in the thymus ( Fig. 5E ; P ¼ 0.0357). In conclusion, our data indicate that, in contrast to the skeletal muscles and some non-skeletal muscle tissues, skin and thymus are highly affected by Smchd1 haploinsufficiency.
High DUX4 expression in the thymus of D4Z4-2. 
DUX4 is highly expressed in keratinocytes
To determine what cell type in muzzle skin expresses DUX4, we isolated total skin from D4Z4-2.5 and D4Z4-2.5/Smchd1
MommeD1 neonates and separated dermis and epidermis to isolate fibroblasts and keratinocytes, respectively. Interestingly, DUX4
transcript levels were very high in keratinocytes (Cq values around 26 in proliferating keratinocytes; Cq values around 24 in keratinocytes that were differentiated for 7 days), while DUX4 expression in fibroblasts was low (Cq values around 33). We also observed higher DUX4 transcript levels in fibroblasts, proliferating keratinocytes, and differentiated keratinocytes of D4Z4-2.5/Smchd1 MommeD1 mice compared with D4Z4-2.5 mice (Fig. 6A) . We next tested the transcript levels of two keratinocyte differentiation markers, keratin 14 (Krt14) and transglutaminase 1 (Tgm1), in the muzzle skin of D4Z4-2.5 and D4Z4-2.5/ Smchd1 MommeD1 mice. We detected increased transcript levels for both markers in the muzzle skin of D4Z4-2.5/ Smchd1 MommeD1 mice compared with D4Z4-2.5 mice ( Fig. 6B; P < 0.05). Finally, we tested DUX4 protein in the muzzle skin of the mice by immunofluorescence staining of muzzle skin sections. So far, we and others have not been able to detect DUX4 protein in tissues of the D4Z4-2.5 mouse. This is most likely due to low DUX4 transcript levels in combination with the lack of a sensitive assay to detect DUX4 protein. Only after isolating muscle fibres from the EDL muscle and generating myotube cultures, DUX4 protein could be detected in sporadic muscle nuclei (15) . As DUX4 transcript levels are high in the muzzle skin of D4Z4-2.5/Smchd1 MommeD1 mice, we expected that we could detect DUX4 protein by immunofluorescence staining. Indeed, we found that the epidermal cell layer of muzzle skin, mainly consisting of keratinocytes, of D4Z4-2.5/Smchd1 MommeD1 mice expresses DUX4 protein (Fig. 6C ). In contrast, we did not detect appreciable DUX4 protein in muzzle skin of wild-type and D4Z4-2.5 mice, even though DUX4 transcript levels were also relatively high in the muzzle skin of D4Z4-2.5 mice. Our results suggest that high DUX4 expression in combination with reduced Smchd1 levels in the skin may affect the keratinization process in mice.
Discussion
Previously, we described the D4Z4-2.5 mouse model that carries an FSHD-sized D4Z4 repeat array of 2.5 units. Although these transgenic mice can be used to study the in vivo epigenetic regulation of the D4Z4 repeat array locus, the expression of DUX4 in skeletal muscles is low and no muscular dystrophy phenotype has been observed (15) . Interestingly, variants in SMCHD1 have not only been identified in FSHD2 patients, but also in FSHD1 patients. FSHD patients with both a contracted D4Z4 repeat array and a SMCHD1 mutation present with an unusually high clinical severity and potentially higher DUX4 transcript levels in skeletal muscles as suggested by SMCHD1 knockdown experiments in FSHD1 myotube cultures (13) . By crossbreeding hemizygous D4Z4-2.5 female mice with heterozygous Smchd1 MommeD1 male mice (20) , we expected to detect increased DUX4 expression in skeletal muscles of D4Z4-2.5/ Smchd1 MommeD1 mice, and possibly muscle pathology.
The analysis of Smchd1 transcript levels in a diverse set of tissues revealed reduced Smchd1 expression in mice carrying the Smchd1 MommeD1 mutation. In addition, we found reduced DNA methylation levels in the region immediately distal to the D4Z4 repeat array and a more open chromatin structure at the D4Z4 repeat array, as measured by the chromatin compaction score (H3K9me3 level corrected for H3K4me2 level). However, only two CpG dinucleotides in the region distal to the D4Z4 repeat array (25) were differentially methylated between D4Z4-2.5 and D4Z4-2.5/Smchd1 MommeD1 mice. It will be interesting to determine why specific CpG dinucleotides seem more sensitive to the presence of the Smchd1 MommeD1 mutation. This may provide insight in the epigenetic regulation of the D4Z4 repeat array locus by SMCHD1, as it is currently unknown how SMCHD1 exactly affects the chromatin structure of the D4Z4 repeat array. The advantage of using the D4Z4-2.5 and D4Z4-2.5/Smchd1 MommeD1 mouse models for such studies is that the mouse genome, unlike the human genome, does not contain D4Z4-like repeat units scattered throughout the genome. Furthermore, our data show that the epigenetic regulation of the D4Z4 transgene in D4Z4-2.5 and D4Z4-2.5/Smchd1 MommeD1 mice parallels the epigenetic regulation observed in humans (15) . We observed that the genotype distribution was distorted on postnatal day 12 when crossbreeding a male heterozygous Smchd1
MommeD1 mouse with a female hemizygous D4Z4-2.5 mouse. Our data suggest that fewer D4Z4-2.5/Smchd1
MommeD1 are born from such crossbreedings. However, additional pups need to be genotyped to confirm this observation. We did not genotype pups before postnatal day 12 as we did not want to disturb the nest. Therefore, some D4Z4-2.5/Smchd1
MommeD1 pups may have died between birth and 12 days of age, although we did not often observe dead pups in the cages. Alternatively, D4Z4-2.5/Smchd1 MommeD1 mice may have died during embryogenesis, and this is currently under study. It will be interesting to analyse offspring from reciprocal crosses, since Smchd1 has a role in X chromosome inactivation (21) . The analysis of DUX4 transcript levels in a set of skeletal muscles, and in myoblast and myotube cultures generated from the EDL muscle, showed us that DUX4 expression is potentially increased in skeletal muscles of D4Z4-2.5/Smchd1
MommeD1 mice compared with D4Z4-2.5 mice. However, DUX4 transcript levels in skeletal muscles of D4Z4-2.5/Smchd1 MommeD1 mice were very low and we observed high interindividual variability in DUX4 expression. Furthermore, we did not observe muscle pathology in skeletal muscles of D4Z4-2.5/Smchd1 MommeD1 mice nor in skeletal muscles of D4Z4-2.5/Smchd1 CKO mice. Therefore, we believe that skeletal muscles of D4Z4-2.5 mice are relatively insensitive to reduced Smchd1 levels. Alternatively, high DUX4 RNA and protein expression may only be measured in this mouse model during skeletal muscle regeneration. We recently showed that intramuscular cardiotoxin injections resulting in severe muscle damage and skeletal muscle regeneration were associated with significantly transient increased DUX4 transcript levels in the D4Z4-2.5 mouse model during early muscle regeneration (31) . Due to the severe phenotype of D4Z4-2.5/ Smchd1 MommeD1 mice, we have refrained from performing similar experiments in these mice. However, it would be interesting to determine how Smchd1 haploinsufficiency affects DUX4 expression during in vivo skeletal muscle regeneration. Finally, our previous studies showed that DUX4 protein expression in D4Z4-2.5 mice is restricted to Myog-negative myoblasts; these cells do not fuse into myotubes (15) . This contrasts with DUX4 protein expression in human myoblasts where DUX4-positive cells are typically myosin-positive and thus part of fused myotubes (18, 19) . A mouse model with DUX4 protein expression in myosin-positive cells may thus respond differently to Smchd1 haploinsufficiency in skeletal muscles, and may serve as a better model to study the modifier role of Smchd1 in the muscle phenotype. For example, a novel mouse model with musclespecific doxycycline-regulated DUX4 expression that was recently generated presents with DUX4-positive nuclei surrounded by myosin heavy chain-positive cytoplasm (17) . Unfortunately, this mouse model lacks a D4Z4 repeat array to which Smchd1 can bind and thus cannot be used to study Smchd1 haploinsufficiency in skeletal muscles.
In contrast to what we observed in skeletal muscles, Smchd1 haploinsufficiency impacts the skin and thymus of D4Z4-2.5 mice. We detected increased DUX4 transcript levels in muzzle skin and primary fibroblasts and keratinocytes isolated from D4Z4-2.5/Smchd1
MommeD1 mice. In addition, D4Z4-2.5/
Smchd1
MommeD1 mice presented with a severe skin phenotype starting from postnatal day 10, especially around the muzzle and on the paws. The eyelids were also affected as shown by histopathological examination and D4Z4-2.5/Smchd1
MommeD1 mice had difficulties opening their eyes. These data give us the opportunity to explain the uncharacterized eye phenotype that was previously described for D4Z4-2.5 mice (15), since a similar, albeit milder, skin phenotype was detected in D4Z4-2.5 mice at 9 weeks of age. Furthermore, we detected increased DUX4 expression in the thymus of D4Z4-2.5/Smchd1 MommeD1 mice.
Interestingly, not all D4Z4-2.5/Smchd1 MommeD1 mice presented with higher thymic DUX4 transcript levels than D4Z4-2.5 mice, and we identified an inverse relationship between DUX4 expression in the thymus and body weight. In addition, the D4Z4-2.5/Smchd1 MommeD1 mice with very high thymic DUX4 transcript levels lost body weight so rapidly from postnatal day 12 that they had to be euthanized on postnatal day 15, while the body weight of the D4Z4-2.5/Smchd1 MommeD1 mice with lower DUX4 expression in the thymus was still increasing at postnatal day 15. It is interesting that D4Z4-2.5/Smchd1 MommeD1 mice show skin and runting phenotypes, as this is not the first DUX4 expressing mouse model with these phenotypes. A mouse model carrying a doxycycline-inducible transgene that encodes DUX4 and 3' genomic DNA, integrated into the mouse X chromosome, displays a variety of phenotypes including increased epidermal thickness and nuclear density in the dermis, and reduced body weight (24) . In addition, a recent study of these iDUX4(2.7) mice showed that females are hyperactive and have significantly impaired hearing loss at high frequencies, while males show periods of increased respiration and catatonic torpor (32). We have not yet investigated these non-skeletal muscle phenotypes in D4Z4-2.5/Smchd1 MommeD1 mice, but it may be worthwhile to study this in more detail because of the overlap in skin and runting phenotypes between the iDUX4(2.7) mouse model and the D4Z4-2.5/Smchd1
MommeD1 mouse model. Overall, we conclude that haploinsufficiency for Smchd1 exacerbates the phenotype of the D4Z4-2.5 mouse model. However, the phenotype of D4Z4-2.5/Smchd1
MommeD1 mice is still restricted to specific tissues, as was already observed in the D4Z4-2.5 mouse (15). This study shows that Smchd1 haploinsufficiency aggravates the phenotype of the D4Z4-2.5 mouse model, a transgenic mouse model for FSHD1. Notably, our data reveal that the skin and the thymus of this mouse model are very sensitive to reduced Smchd1 levels, while skeletal muscles seem unaffected. To study muscle pathology associated with FSHD, other mouse models will need to be studied, such as the recently generated mouse model with muscle-specific doxycycline-regulated DUX4 expression (17) . However, our study provides support that the D4Z4-2.5 mouse model can be used to study the epigenetic regulation of the D4Z4 repeat array. In addition, the D4Z4-2.5/ Smchd1
MommeD1 mouse model may be ideal to study the function of DUX4 in the epidermis and the thymus. Interestingly, DUX4 expression was recently reported in human skin and confluent keratinocytes. ChIP sequencing analysis showed that repressive H3K9me3 levels at the D4Z4 repeat array, both at chromosome 4q35 and chromosome 10q26, dropped significantly during confluence-induced squamous differentiation. Western blot analysis and immunohistochemistry detected DUX4 protein in keratinocytes in the epidermis of a control individual, and the full-length DUX4 transcript was also detected in confluent keratinocytes (33) . Another study reported DUX4 expression, together with expression of the DUX4 target genes TRIM43 and MBD3L2, in human thymus (34) . In conclusion, DUX4 may have a function outside the germline.
Materials and Methods

D4Z4-2.5/Smchd1
MommeD1 mice D4Z4-2.5 mice and Smchd1 MommeD1 mice were generated previously (15, 20) . All D4Z4-2.5/Smchd1 MommeD1 mice were obtained by crossbreeding a male heterozygous Smchd1 MommeD1 mouse with a female hemizygous D4Z4-2.5 mouse. Resulting offspring were genotyped by PCR analysis using tail DNA. The D4Z4-2.5 transgene was detected by PCR using the following primers: 5'-TGGTCCGTGAAGACATGTGT-3' and 5'-GAGCCCTCAGAGAAGT GGG-3'. The Smchd1 MommeD1 mutation was detected by PCR with the following primers: 5'-CAATAGGTCCCCCTCATCAA-3' and 5'-CAGTGGCCAACCACATAACA-3'. An internal probe with the sequence 5'-CAACATAACAGCACAACCAAAGCTG-3' was added to the PCR mixture so that after the reaction the PCR product could be melted by Lightscanner (Idaho Technology Inc., Salt Lake City, USA) resulting in different melt curves for alleles with the Smchd1 MommeD1 mutation and for alleles without the Smchd1 MommeD1 mutation. Wild-type mice, Smchd1
MommeD1 mice, and D4Z4-2.5 mice of the same genetic background as the D4Z4-2.5/Smchd1 MommeD1 mice were used as controls. All mice were bred at the animal facility of the Leiden University Medical Center. Mice were housed in individually ventilated cages with a standard 12h/12h light/dark cycle. Standard rodent chow and water were available ad libitum. All experiments were approved by the Animal Experiments Committee of the LUMC.
Smchd1 fl/fl mice and Smchd1
Del/þ mice A Smchd1 targeting construct that introduced loxP sites surrounding exon 4 of Smchd1 and a neomycin cassette flanked by Frt sites was produced by recombineering. The targeting construct was electroporated into Bruce4 C57BL/6 embryonic stem cells. Neomycin-resistant clones were screened by Southern blot for their integrations at the 5' and 3' ends, using PCR amplified probes (5'-probe amplified with 5'-CTAAGCCCAGAACCTTG CAC-3' and 5'-CTTGAAAGCAGACAGGCTCA-3'; 3'-probe amplified with 5'-GCCCATTATTCCTCCAAACA-3' and 5'-GAATTTGCA TTTGGAAAGGA; each probe was cloned into a TOPO TA vector). The DNA was then cut with BssSI for the 5'-probe, and with BssSI, BglII, NcoI, and KpnI for the 3'-probe. One correctly targeted clone was used to produce mice by blastocyst injection. The neomycin cassette was removed by crossing with the Rosa26-FLPe knockin mouse strain (35) . The Smchd1 fl allele was maintained on a C57BL/6 background. The Smchd1 Del allele was generated by crossing with a constitutive CMV-driven Cre recombinase mouse strain (28) , and was also maintained on a C57BL/6 background. All mice were produced and maintained under approval by The Walter and Eliza Hall Institute of Medical Research Animal Ethics Committee (AEC 2014.026).
D4Z4-2.5/Smchd1 CKO mice
Mice expressing Cre recombinase from the muscle-specific Myf5 locus have been described previously (27) . The Smchd1 conditional knock-out line (Smchd1 fl/fl mice) is described above.
Progeny positive for the D4Z4-2.5 transgene, hemizygous or negative for Myf5-Cre recombinase, and homozygous for floxed Smchd1 were produced by a series of crossbreedings and identified by PCR analysis using toe DNA. 
Isolation and culturing of neonatal fibroblasts and keratinocytes
Neonatal mice were euthanized by decapitation followed by removal of the complete skin. Primary fibroblasts and primary keratinocytes were isolated following the protocol supplied by the manufacturer (CELLnTEC; Bioconnect, Huissen, the Netherlands). In short, the skin of the mice was removed, followed by overnight incubation in a dispase solution containing antibiotics and antimycotics (CELLnTEC; Bioconnect, Huissen, the Netherlands). The next day, the epidermis and dermis were separated using forceps. The dermis was next cut into small pieces and distributed over a 60 mm dish with addition of a small amount of DMEM/F12 medium (Thermo Fisher Scientific, Bleiswijk, the Netherlands) supplemented with 1% penicillinstreptomycin (Sigma Aldrich, Zwijndrecht, the Netherlands) and 20% heat-inactivated foetal bovine serum (Thermo Fisher Scientific, Bleiswijk, the Netherlands). Over the course of the week, primary fibroblasts grew out of the dermis pieces. Upon confluence, the cells were transferred to a 100 mm dish and the dermis pieces were discarded. The epidermis was incubated for 20-30 min at room temperature in Accutase (CELLnTEC; Bioconnect, Huissen, the Netherlands). After this incubation step, the epidermis was gently rubbed in a 60 mm dish to obtain single cells. These cells were then centrifuged for 5 min at room temperature and seeded at a density of 4Â10 4 cells/cm 2 in a 6-well plate containing CnT-PR medium (CELLnTEC; Bioconnect, Huissen, the Netherlands). One day before confluence, cells were either harvested (proliferating keratinocytes) or the medium was changed to CnT-PR-D medium (CELLnTEC; Bioconnect, Huissen, the Netherlands). At confluence, 1.2 mM Ca2 þ was added to the medium to drive differentiation.
Differentiated keratinocytes were harvested 7 days after changing the medium to CnT-PR-D medium.
Isolation and culturing of EDL single muscle fibres
Mice were euthanized by cervical dislocation followed by dissection of the EDL muscle from tendon to tendon. Next, the EDL muscle was digested twice in 0.2% collagenase (Sigma Aldrich, Zwijndrecht, the Netherlands) in DMEM medium (Thermo Fisher Scientific, Bleiswijk, the Netherlands) supplemented with 1% penicillin-streptomycin (Sigma Aldrich, Zwijndrecht, the Netherlands) at 37 C for 105 and 120 min, respectively. The resulting fibres were dissociated using Pasteur pipettes with different apertures, followed by several washing steps as described previously (36) . Next, 150 individual fibres were cultured on matrigel-coated (BD, Breda, the Netherlands) 6-well plates in DMEM medium supplemented with 30% foetal bovine serum, 10% horse serum, 1% penicillin-streptomycin, 1% chicken embryo extract, and 2.5 ng/ml fibroblast growth factor (all Thermo Fisher Scientific, Bleiswijk, the Netherlands). The fibres were detached and removed after 3 days. The attached myoblasts were trypsinised, counted, and plated for experiments. Differentiation of myoblasts into myotubes was induced after 48 h by replacing the original medium with DMEM medium supplemented with 2% horse serum and 1% penicillinstreptomycin (both Thermo Fisher Scientific, Bleiswijk, the Netherlands). At the same time, myoblasts were harvested. 48 h post-differentiation, myotubes were harvested.
Quantitative DNA methylation analysis by bisulphite conversion sequencing
Bisulphite treatment was performed on 400 ng of genomic DNA isolated from mouse tail and we used the EZ DNA MethylationLightning kit (Zymo Research; BaseClear Lab Products, Leiden, the Netherlands). DNA methylation levels of the D4Z4-2.5 transgene were quantified by PCR analysis using the following primers: 5'-ATAGGGAGGGGGTATTTTA-3' and 5'-ACRATCAAAAAC ATACCTCTATCTA-3' (25) . Next, the PCR product was ligated into the TOPO TA vector (Thermo Fischer Scientific, Bleiswijk, the Netherlands), followed by transformation of the ligation product in DH5a bacteria, and Sanger sequencing of plasmid DNA isolated from individual colonies. 10 individual colonies 
were picked for each DNA sample and sent for Sanger sequencing.
Smchd1 and histone ChIP analyses
We followed a previously published protocol with minor modifications (37) . In short, confluent cultures of neonatal fibroblasts (three 150 mm plates) were crosslinked in 1% formaldehyde for 10 min at room temperature followed by quenching of the reaction with 125 mM glycine for 5 min at room temperature. 
RNA isolation and cDNA synthesis
Total RNA was isolated from different mouse tissues and cells using the miRNeasy kit (Qiagen, Venlo, the Netherlands) according to the manufacturer's instructions and included a DNase treatment. RNA concentrations were determined with a Nanodrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Bleiswijk, the Netherlands). 1-3 lg of total RNA was reverse transcribed using the RevertAid H Minus First Strand cDNA synthesis kit with Oligo(dT)18 primers (both Thermo Fisher Scientific, Bleiswijk, the Netherlands), according to the instructions of the manufacturer. The resulting cDNA was treated with 2 units of RNaseH (Thermo Fisher Scientific, Bleiswijk, the Netherlands) at 37 C for 20 min and diluted in 100 ll H 2 O. 2-5 ll of the diluted cDNA was used for quantitative RT-PCR analysis.
Quantitative RT-PCR analysis
RT-PCR analysis was performed in duplicate using the CFX96 system (Bio-Rad, Veenendaal, the Netherlands) with SYBR green mastermix and 0.5 pM of each primer in a 15 ll final reaction volume. All primers, spanning at least one intron, were designed using Primer3 software. Primer sequences for all reactions are listed in Table 2 . The following cycling conditions were used: an initial denaturation step at 95 C for 3 min followed by 40 cycles of 10 s at 95 C and 45 s at primer Tm. Next, a melting curve analysis was performed to determine the specificity of all reactions. This analysis consisted of an initial denaturation step at 95 C for 3 min followed by 1 min incubation step at 65 C and sequential temperature increments of 0.5 C from 65-95 C.
Results were analysed with Bio-Rad CFX Manager version 3.1 (Bio-Rad, Veenendaal, the Netherlands) and normalized to the reference gene Rpl27 (Fig. 3F and G) or to the reference genes Gapdh and Rpl13a (all other figures) to correct for cDNA input.
Flow cytometry of the GFP3C transgene
Mice were tailed at three weeks of age and a drop of blood was diluted in PBS. Flow cytometry was next performed to analyse GFP expression in red blood cells (20) . All mice analysed were hemizygous for the GFP3C transgene, and the GFP3C line of mice has been backcrossed for more than 10 generations from FVB/N background to C57BL/6 background.
Smchd1 Western blot
Whole E12.5 embryos were harvested from intercrosses between Smchd1 Del/þ mice. Embryo tail DNA was used for genotyping. Embryos were lysed and prepared for western blot as described previously (38) . Smchd1 was detected with two different Smchd1 antibodies (Bethyl labs A302-871A at 1/2000 dilution or Abcam ab31865 at 1/2000 dilution). An actin antibody was included as a control (Santa Cruz sc1616 at 1/1000 dilution).
H&E staining of skeletal muscles
Skeletal muscles were dissected and frozen in isopentane cooled to À165 C. Next, five-micron cryosections were cut, followed by H&E staining consisting of a 5 min incubation in haematoxylin, 1 min incubation in eosin, and several washing steps with dH 2 O, ethyl alcohol, and xylene. H&E-stained sections were analysed by light microscopy (Leica Microsystems B.V., Rijswijk, the Netherlands).
DUX4 staining of muzzle skin
Muzzle skins were dissected and frozen in isopentane cooled to À165 C. Cryosections were cut at 5 mm thickness and placed on Superfrost Plus glasses (Thermo Fisher Scientific, Bleiswijk, the Netherlands). The sections were fixed with 4% formaldehyde in PBS for 10 min at room temperature and washed three times in PBS/0.5% Tween for 5 min. Next, the samples were blocked with 10% normal goat serum (Agilent, Amstelveen, the Netherlands) for 30 min and incubated with primary rabbit DUX4 antibody directed against the C-terminal region of DUX4 (E5.5; 1: 300 in PBS/0.1% BSA) (39) . After a triple wash in PBS/0.5% Tween for 3 min, Alexa 488 donkey anti-rabbit (Thermo Fisher Scientific, Bleiswijk, the Netherlands; diluted 1: 100 in PBS/ 0.1%BSA) was applied for 30 min in the dark. The excess was removed by a triple PBS/0.5% Tween wash. Finally, the sections were incubated with PBS/dapi (500 ng/ml) for 15 min in the dark, washed 3 min with PBS/0.5% Tween and mounted with Aqua Poly/Mount (Polysciences Europe GmbH, Hirschberg an der Bergstrasse, Germany). The stained sections were analysed on a Leica DMRA2 microscope (Leica Microsystems B.V., Rijswijk, the Netherlands).
Histopathological examination
Complete necropsy was performed on mice that were 15 days or 9 weeks of age. Next, tissues were fixed in 4% neutral buffered formalin, and bone tissues were subjected to an additional decalcification step by incubation in formic acid for 5 days. Successively, all tissues were embedded in paraffin, sectioned at five micron, stained with H&E, and evaluated by light microscopy following standard procedures (40, 41) .
Flow cytometry of thymocytes
Single cell suspensions of thymocytes were obtained by homogenization of the thymus over 70 lm strainers (VWR International B.V., Amsterdam, the Netherlands). Cells were washed with phosphate-buffered saline containing 2% foetal bovine serum and subsequently stained with aCD8a-Efluor450, aCD4-PerCP-Cy5.5, aCD25-PE and aCD44-APC (all Thermo Fisher Scientific, Bleiswijk, the Netherlands) for 20 min at 4 C. After an additional washing step, flow cytometry was performed on a Canto II instrument (Becton Dickinson B.V., Vianen, the Netherlands) and analysed using FlowJo software (Becton Dickinson B.V., Vianen, the Netherlands).
Statistical analysis
Statistical analysis was performed using GraphPad Prism software (version 7.00; GraphPad Software, Inc., La Jolla, USA). Most data sets were compared using unpaired Student's t-tests or Mann-Whitney U tests, depending on whether the data were normally distributed (normality was determined by ShapiroWilk normality tests). The D4Z4 DNA methylation levels were compared using Student's t-tests; multiple testing correction was performed by Holm-Sidak multiple comparison tests.
Genotype and gender distribution was tested by Pearson's chisquared test. Body weight was tested by one-way analysis of variance (ANOVA) followed by Tukey post hoc test. Percentage of different cell populations in the thymus was tested by twoway ANOVA followed by Holm-Sidak multiple comparison tests.
